Latest tumor lysis syndrome Stories
-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory
SHENYANG, China, Nov. 29, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.
ROME, June 18 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ --Ardea Biosciences, Inc.
BRIDGEWATER, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced that the U.S.
First new treatment option in 40 years for chronic management of condition DEERFIELD, Ill., March 12 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc.
- Results Presented at ASH Annual Meeting - SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology.